Vaccines and Global Health: The Week in Review :: 15 January 2022

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

WHO – 150th session of the Executive Board

WHO – 150th session of the Executive Board
24 – 29 January 2022
Virtual event
EB150 Main Documents [Selected]
EB150/1
Provisional agenda

EB150/1 (annotated)
Provisional agenda (annotated)

EB150/7
Political declaration of the third high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases

EB150/7 Add.1
Political declaration of the third high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases

EB150/8
The global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections

EB150/9
Global strategy for tuberculosis research and innovation

EB150/10
Road map for neglected tropical diseases 2021–2030

EB150/11
Immunization Agenda 2030

EB150/12
Infection prevention and control

EB150/13
Global road map on defeating meningitis by 2030

EB150/15
Strengthening WHO preparedness for and response to health emergencies

EB150/17
Standing Committee on Pandemic and Emergency Preparedness and Response

EB150/18
Public health emergencies: preparedness and response
WHO’s work in health emergencies

EB150/19
Influenza preparedness

EB150/20
Global Health for Peace Initiative

EB150/21
Poliomyelitis
Poliomyelitis eradication

EB150/22
Poliomyelitis
Polio transition planning and polio post-certification

EB150/23
Maternal, infant and young child nutrition
Comprehensive implementation plan on maternal, infant and young child nutrition: biennial report

Wellcome’s new strategy gets extra boost, as organisation makes strongest returns in over two decades

Wellcome’s new strategy gets extra boost, as organisation makes strongest returns in over two decades
10 January 2022
Wellcome is making its biggest funding commitment to science and health in our 85-year history, thanks to our strongest investment returns in 25 years.

 

With an investment portfolio now worth £38.2 billion, we are planning to raise our charitable spending to £16 billion over the next decade to fund science that supports a healthy future for everyone.  

We have also committed an extra £750 million to fund large-scale, high-impact activities across five years, which we anticipate will grow to £1 billion next year.

As a growing organisation, we want to scale up in a deliberate and sustainable way, ensuring that we can consistently fund research to improve health in all economic climates.

“These returns mark a step-change in Wellcome’s ability to fund and support new discoveries in science and health, and help solve three of the great challenges of the 21st century – climate change, infectious diseases and mental health. With plans to spend £16 billion on our mission over the next decade, we will be increasing our spending from the previous decade by more than 50 per cent. This gives us a huge opportunity to increase our support for scientific research that will make a real difference to people everywhere in the years to come.” Said Jeremy Farrar, Director, Wellcome.

The funding is a major boost for Wellcome’s new, more streamlined strategy, which focuses on three worldwide health challenges – mental health, infectious disease, and the health impacts of climate change. Underpinning it all is a broad programme of discovery research, which aims to give researchers the freedom to search for new knowledge.

Over the past year, we have also significantly increased our global policy and advocacy capacity in order to connect with governments worldwide and drive systemic change. This has included expanding our European presence, through our Europe Office in Berlin.

As part of our new direction, we will seek to support cross-sector, cutting-edge collaborations. For example, the public-private Coalition for Epidemic Preparedness Innovations (CEPI), which we co-founded in 2017, has played a pivotal role in pandemic preparedness and the Covid-19 response, bringing together a diverse range of global actors to support Covid-19 vaccine development and equity.

We also want to fund research that has the potential to change the way we understand life. As part of our £150 million commitment to the Covid-19 pandemic, we have supported genomics researchers to keep up with the virus. The Wellcome Sanger Institute was at one point responsible for half of the world’s Covid-19 sequencing, and funding genomics research in East Africa has generated the first Covid-19 data in places like South Sudan and Burundi.

Solving the most urgent health challenges of this century will take time, but our long-term approach will support researchers as they grapple with some of the biggest health questions facing us all.

Global Growth to Slow through 2023, Adding to Risk of ‘Hard Landing’ in Developing Economies – World Bank

Editor’s Note:
Global pandemic response — its unprecedented successes counterbalanced by inequities, incoherence and incompetence — is impacting the macroeconomic context as below. Developing economies — facing decisions on incurring more debt to finance continuing purchase of COVID vaccines and emerging therapeutics — face difficult tradeoffs as global growth falters, and country economies and health systems face mounting stressors.

 

Global Growth to Slow through 2023, Adding to Risk of ‘Hard Landing’ in Developing Economies – World Bank
Spread of COVID-19 Variants Alongside Inflation, Debt, and Inequality Intensifies Uncertainty
WASHINGTON, Jan. 11, 2022—Following a strong rebound in 2021, the global economy is entering a pronounced slowdown amid fresh threats from COVID-19 variants and a rise in inflation, debt, and income inequality that could endanger the recovery in emerging and developing economies, according to the World Bank’s latest Global Economic Prospects report. Global growth is expected to decelerate markedly from 5.5 percent in 2021 to 4.1 percent in 2022 and 3.2 percent in 2023 as pent-up demand dissipates and as fiscal and monetary support is unwound across the world.

 

The rapid spread of the Omicron variant indicates that the pandemic will likely continue to disrupt economic activity in the near term. In addition, a notable deceleration in major economies—including the United States and China—will weigh on external demand in emerging and developing economies. At a time when governments in many developing economies lack the policy space to support activity if needed, new COVID-19 outbreaks, persistent supply-chain bottlenecks and inflationary pressures, and elevated financial vulnerabilities in large swaths of the world could increase the risk of a hard landing.

“The world economy is simultaneously facing COVID-19, inflation, and policy uncertainty, with government spending and monetary policies in uncharted territory. Rising inequality and security challenges are particularly harmful for developing countries,” said World Bank Group President David Malpass. “Putting more countries on a favorable growth path requires concerted international action and a comprehensive set of national policy responses.”

The latest Global Economic Prospects report features analytical sections that provide fresh insights into three emerging obstacles to a durable recovery in developing economies. The first, on debt, compares the latest international initiative to tackle unsustainable debt in developing economies—the G20 Common Framework—with previous coordinated initiatives to facilitate debt relief. Noting that COVID-19 pushed total global debt to the highest level in half a century even as the creditors’ landscape became increasingly complex, it finds that future coordinated debt relief initiatives will face higher hurdles to success. Applying lessons from the past restructurings to the G20 Common Framework can increase its effectiveness and avoid the shortcomings faced by earlier initiatives.

The choices policymakers make in the next few years will decide the course of the next decade,” said Mari Pangestu, the World Bank’s Managing Director for Development Policy and Partnerships. “The immediate priority should be to ensure that vaccines are deployed more widely and equitably so the pandemic can be brought under control. But tackling reversals in development progress such as rising inequality will require sustained support. In a time of high debt, global cooperation will be essential to help expand the financial resources of developing economies so they can achieve green, resilient, and inclusive development.”

…The third analytical section explores COVID-19’s impact on global inequality. It finds that the pandemic has raised global income inequality, partly reversing the decline that was achieved over the previous two decades. It has also increased inequality in many other spheres of human activity—in the availability of vaccines; in economic growth; in access to education and health care; and in the scale of job and income losses, which have been higher for women and low-skilled and informal workers. This trend has the potential to leave lasting scars: for example, losses to human capital caused by disruptions in education can spill over across generations.

Ayhan Kose, Director of the World Bank’s Prospects Group, said: “In light of the projected slowdown in output and investment growth, limited policy space, and substantial risks clouding the outlook, emerging and developing economies will need to carefully calibrate fiscal and monetary policies. They also need to undertake reforms to erase the scars of the pandemic. These reforms should be designed to improve investment and human capital, reverse income and gender inequality, and cope with challenges of climate change.”

Global Growth Prospects – Flagship Report January 2022 :: 240 pages
PDF: https://openknowledge.worldbank.org/bitstream/handle/10986/36519/9781464817601.pdf

General Council discusses India’s call for virtual ministerial meeting on pandemic response

Editor’s Note:
We continue to monitor [in distressed amazement] the pace of WTO engagement on probably the single most important issue it has faced in the last quarter century.

WTO – World Trade Organisation [to 15 Jan 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
General Council discusses India’s call for virtual ministerial meeting on pandemic response
10 January 2022
General Council Chair Ambassador Dacio Castillo (Honduras) convened the 10 January meeting in response to India’s recent proposal to hold a virtual Ministerial Conference on the WTO’s response to the COVID-19 pandemic, including a proposed waiver of relevant intellectual property protections. At the meeting, Director-General Ngozi Okonjo-Iweala urged WTO members to urgently step up their efforts, suggesting that with the requisite political will, members can in the space of the coming weeks reach multilateral compromises on intellectual property and other issues so that the WTO fully contributes to the global response to COVID-19 and future pandemics.
India on 23 December 2021 sent a letter to the General Council Chair calling for a virtual ministerial meeting to be held on the issue of the WTO response to the pandemic, including the proposal to waive certain provisions of the TRIPS Agreement for COVID-19-related vaccines, therapeutics, and diagnostics (IP/C/W/669/Rev.1). The same day, Ambassador Castillo circulated the letter to all delegations, indicating that he would “conduct consultations and convene an open-ended informal General Council meeting” on the matter during the week of 10 January.
In her remarks, DG Okonjo-Iweala called for urgent action towards a comprehensive WTO outcome on pandemic response. “More than two years have passed since the onset of the pandemic. The emergence of the Omicron variant, which forced us to postpone our Twelfth Ministerial Conference, reminded us of the risks of allowing large sections of the world to remain unvaccinated.”
“We at the WTO now have to step up urgently to do our part to reach a multilateral outcome on intellectual property and other issues so as to fully contribute to the global efforts in the fight against COVID-19,” she added.
DG Okonjo-Iweala updated members on her efforts, together with Deputy Director-General Anabel González, “to support an informal group of members to converge around a meaningful acceptable outcome that can be built upon by the wider membership to bring a successful conclusion to the IP issue.” Work had continued over the holidays, she said. ”It is slow but steady progress, and we are hopeful that this approach can help us together find the direction we need.”
“There is no better time to build convergence than now,” the Director-General added, urging all members to participate actively and constructively in the ongoing processes at the General Council and the TRIPS Council.
She noted that while pandemic response remained the most urgent endeavour facing WTO members, not least given the spectre of even newer coronavirus variants, many members had reached out to her to emphasise the importance of other items on the WTO agenda, including fisheries subsidies, agriculture and WTO reform. She stressed that these areas remained priorities for outcomes, and expressed hope “that we can all agree on getting results as soon as possible.”
The gathering heard a range of views on the proposed ministerial meeting, notably on timing, issue coverage, and the need to further narrow differences in Geneva ahead of ministerial engagement.
Describing the meeting as “useful,” General Council Chair Ambassador Castillo said he would continue to hold consultations with members on the Indian proposal, underlining “the urgency and importance of reaching a meaningful outcome. ”A common WTO response to COVID-19 “remains an urgent priority for the membership,” he said.

Therapeutics and COVID-19: living guideline

COVID Therapeutics

Therapeutics and COVID-19: living guideline
WHO 14 January 2022
Overview
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.
This eighth version of the WHO living guideline now contains 14 recommendations, including three new recommendations regarding Janus kinase (JAK) inhibitors and sotrovimab. No further updates to the previous existing recommendations were made in this latest version.

 

::::::

WHO recommends two new drugs to treat COVID-19
14 January 2022 Geneva
Statement
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.

The first drug, baricitinib, is strongly recommended for patients with severe or critical COVID-19. It is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress the overstimulation of the immune system. WHO recommends that it is given with corticosteroids.

Baricitinib is an oral drug, used in the treatment of rheumatoid arthritis. It provides an alternative to other arthritis drugs called Interleukin-6 receptor blockers, recommended by WHO in July 2021.
WHO has also conditionally recommended the use of a monoclonal antibody drug, sotrovimab, for treating mild or moderate COVID-19 in patients who are at high risk of hospitalization. This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.

Sotrovimab is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail recommended by WHO in September 2021. Studies are ongoing on the effectiveness of monoclonal antibodies against Omicron but early laboratory studies show that sotrovimab retains its activity.

The panel of experts developing the guidelines also looked at two other drugs for severe and critical COVID-19: ruxolitinib and tofacitinib. Given their uncertain effects, WHO made a conditional recommendation against their use.

 

Today’s recommendations, forming the eighth update of WHO’s living guidelines on therapeutics and COVID-19, are based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19.

WHO is in discussions with manufacturers to secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics. The Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics pillar has been engaging with pharmaceutical companies to seek comprehensive access plans for low- and middle-income countries, so that these treatments can be rapidly deployed everywhere, not just in rich countries. The ACT-A is also looking to expand licensing scope to make the products more affordable.

The two newly recommended drugs – baricitinib and sotrovimab – have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries. 

 

::::::

Editor’s Note:
We reviewed WHO COVID and ACT Tool Accelerator websites to identify additional detail on the “WHO discussions” involving manufacturers referenced above [regarding global supply capacity and equitable and sustainable access to treatments/therapeutics]. We found no announcements or additional detail.

Further, we reviewed the Outcomes Statement of the 8th ACT-Accelerator Facilitation Council meeting of 9 December 2021. The statement makes no mention of discussions on supply and equitable access to COVID therapeutics.

We also note that the Access to COVID-19 tools funding commitment tracker [see full announcement below] reports that the “Therapeutics” ACT-A 2021-22 budget of US$3.5 billion has received contributions of only USD$.06 billion as if January 7, 2022, a USD$3.44 billion shortfall.

Finally, we note that the ACT-Accelerator Strategic Plan & Budget: October 2021 to September 2022 [28 October 2021] addresses therapeutics:
3.3 Therapeutics
Co-convened by Unitaid and Wellcome, with WHO
The Therapeutics Pillar supports access to safe and effective therapeutics of assured quality to save
millions of lives from COVID-19 and to minimise its global health and economic threat.

Context. With the challenges of an evolving pandemic and difficulty in large scale uptake of
vaccines, therapeutics will remain critical in the COVID-19 response, saving lives and reducing
the burden on health systems (see Section 1). Among existing options, medical oxygen and
corticosteroids are mainstays of treatment for severe and critical COVID-19, along with
recent additions to clinical guidelines. ACT-A is working to drive uptake of existing products
and support equitable access to novel therapies for LICs and LMICs – despite challenges in
supply, price, and implementation. To date, there have been few recommended therapeutics
to treat mild and moderate cases in outpatient settings. But if proven effective, emerging
oral outpatient drugs – deployed with tests -could fundamentally change the response. One
example – subject to clinical review – could be the antiviral compound molnupiravir, for which
promising interim results were recently announced. Effective oral outpatient drugs would offer
a widespread, scalable way to stop disease progression, ease strain on health systems and
reduce deaths.

Setting a target. Approximately 200 million COVID-19 cases are expected globally in the next 12 months20, with potential for increased case numbers due to new variants or continued transmission amongst the vaccinated21. The Therapeutics Pillar aims to treat up to ~120 million22 of these cases (6-8 million severe and 113 million mild / moderate), focusing on LICs, LMICs and UMICs.

Therapeutics Pillar priorities: To achieve that target by September 2022, the Therapeutics
Pillar will prioritize deployment of existing effective products, including medical oxygen for
severe and critical cases, introduction of new COVID-19 therapies once proven, especially
those with a profile conducive to access in LICs and LMICs, and strengthening of research
efforts to enrich the therapeutic clinical pipeline. Alongside this, there will be a need to ensure
country readiness for effective implementation of tools, including supporting a test-and-treat
strategy for outpatient care in eligible patients…

Access to COVID-19 tools funding commitment tracker- WHO

Access to COVID-19 tools funding commitment tracker– WHO
13 January 2022 | Publication :: Download (283.2 kB)
Overview
The ACT-Accelerator Commitment Tracker provides transparent reporting on funding commitments made against ACT-Accelerator Pillar budgets.
Urgent action to address these financing requirements will boost the impact of the ACT-Accelerator achievements to date, fast-track the development and deployment of additional game-changing tools, and mitigate the risk of a widening gap in access to COVID-19 tools between low- and high-income countries.
The tracker is updated every 2 weeks on a Friday and based on data received from ACT-Accelerator Pillar co-conveners. All amounts are in USD and are subject to ForEx variations.
This commitment tracker was prepared by the ACT-A Hub with cooperation from the ACT-A partners.
The ACT-A Hub, hosted by WHO, appreciates the support of Germany and Kuwait in financing our coordination work.

 

Funding Snapshot since 29 October 2021
As of 29 October 2021, an unprecedented mobilization of sovereign funders and private sector, philanthropic and multilateral contributors had galvanized commitments of US$ 18.9 billion. The ACT Accelerator Commitment Tracker provides details of this funding, taking into account retrospective cost adjustments. The 2020-21 budget’s funding gap was US$ 14.3 billion.

Since 29 October 2021, all new pledges in support of the ACT-Accelerator will count towards the 2021-22 budget (see details in ACT-Accelerator Strategic Plan & Budget: October 2021 to September 2022). These pledges, counting towards the 2021-22 budget, total US$ 225 million as of 6 January 2022, bringing the 2021-22 funding gap to US$ 23.2 billion.

Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)

Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)
11 January 2022 Statement
Key messages:
WHO has established the Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) to review and assess the public health implications of emerging SARS-CoV-2 Variants of Concern (VOC) on the performance of COVID-19 vaccines and to provide recommendations to WHO on COVID-19 vaccine composition, as needed.
In the context of the circulation of Omicron SARS-CoV-2 Variant of Concern, the TAG-CO-VAC urges broader access globally to current COVID-19 vaccines for primary series and booster doses, in the hope that this also mitigates the emergence and impact of new VOCs.
The TAG-CO-VAC is considering the strain composition of COVID-19 vaccines, and encourages vaccine developers to gather data on a small scale on the breadth and magnitude of immune response for monovalent and multivalent vaccines against VOCs – this data would then be considered in a broader decision-making framework on vaccine composition by the TAG-CO-VAC.

…The TAG-CO-VAC is developing a framework to analyze the evidence on emerging VOCs in the context of criteria that would trigger a recommendation to change COVID-19 vaccine strain composition and will advise WHO on updated vaccine compositions, as required. This framework considers the global spread and transmissibility, clinical severity, genetic, antigenic and phenotypic characteristics of the VOC, including capacity for immune escape and assessments of vaccine effectiveness.[2]

Since the WHO classified the Omicron variant as a VOC on 26 November 2021, the TAG-CO-VAC has met regularly to review the evidence on the characteristics of the Omicron variant.

 

This statement reflects the current understanding of the implications of the emergence of the Omicron variant on current COVID-19 vaccines and provides the TAG-CO-VACs current perspective on vaccine options for the future…

Composition of current and future COVID-19 vaccines
The TAG-CO-VAC considers that COVID-19 vaccines that have high impact on prevention of infection and transmission, in addition to the prevention of severe disease and death, are needed and should be developed. Until such vaccines are available, and as the SARS-CoV-2 virus evolves, the composition of current COVID-19 vaccines may need to be updated, to ensure that COVID-19 vaccines continue to provide WHO-recommended levels of protection against infection and disease[4] by VOCs, including Omicron and future variants.

 

The TAG-CO-VAC will consider a change in vaccine composition:
to ensure that vaccines continue to meet the criteria established in WHO’s Target Product Profile for COVID-19 vaccines, including protection against severe disease
to improve vaccine-induced protection.

 

To that aim, COVID-19 vaccines need to:
be based on strains that are genetically and antigenically close to the circulating SARS-CoV-2 variant(s);
in addition to protection against severe disease and death, be more effective in protection against infection thus lowering community transmission and the need for stringent and broad-reaching public health and social measures;
elicit immune responses that are broad, strong, and long-lasting in order to reduce the need for successive booster doses.

 

In line with this approach, there are many options to consider:
a monovalent vaccine that elicits an immune response against the predominant circulating variant(s), although this option faces the challenge of the rapid emergence of SARS-CoV-2 variants and the time needed to develop a modified or new vaccine;
a multivalent vaccine containing antigens from different SARS-CoV-2 VOCs;
a pan SARS-CoV-2 vaccine: a more sustainable long-term option that would effectively be variant-proof.

In the interim, the TAG-CO-VAC encourages COVID-19 vaccine manufacturers to generate and provide data on performance of current and Omicron-specific COVID-19 vaccines, including the breadth, magnitude, and durability of humoral and cell mediated immune responses to variants through monovalent and/or multivalent vaccines. These data will be considered in the context of the framework mentioned above to inform the TAG-CO-VAC decisions when changes to vaccine composition may be required. It would be important for vaccine manufacturers to take steps in the short-term for the development and testing of vaccines with predominant circulating variants and to share these data with the TAG-CO-VAC and other relevant WHO expert committees. Vaccine manufacturers are also encouraged to provide such data for any novel and broadly reactive SARS-CoV-2 vaccines that are developed.

The TAG-CO-VAC will continue to assess evidence on the predominant circulating VOC(s) with respect to properties of spread/transmissibility, clinical severity (virulence), genetic, antigenic and phenotypic characteristics of the VOC, including capacity for immune escape and assessments of vaccine effectiveness and impact, and information provided by manufacturers. The TAG-CO-VAC will then advise WHO on COVID-19 vaccine strain composition, which could potentially be developed either as a monovalent vaccine with the predominant circulating variant or a multivalent vaccine derived from different variants.

Addressing the challenge of continuing to ensure the production of the best possible vaccines in a timely manner requires a continuous exchange of information and collaboration between WHO and its expert groups, the TAG-CO-VAC, regulatory authorities, and COVID-19 vaccine manufacturers. WHO, on behalf of its Member States, is committed to facilitating this process.

This statement and its conclusions will be updated by the TAG-CO-VAC as data become available.

Coronavirus [COVID-19] – WHOPublic Health Emergency of International Concern (PHEIC)

Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

 

Weekly Epidemiological and Operational updates
Last update: 14 Jan 2022
Confirmed cases :: 318 648 834
Confirmed deaths :: 5 518 343
Vaccine doses administered: 9 283 076 642

 

::::::

Weekly epidemiological update on COVID-19 – 11 January 2022
Overview
Globally, during the week 3 – 9 January 2022, the new weekly COVID-19 cases increased markedly by 55%, while the new weekly deaths remained similar to those reported during the previous week. This corresponds to over 15 million new cases and over 43,000 new deaths. As of 9 January, over 304 million confirmed cases and over 5.4 million deaths have been reported.
All regions reported an increase in the incidence of weekly cases except for the Africa Region, which reported an 11% decrease. The South-East Asia region reported the largest increase in new cases last week (418%), followed by the Western Pacific Region (122%), the Eastern Mediterranean Region (86%), the Region of the Americas (78%) and the European Region (31%). New weekly deaths increased in the African Region (84%) and Region of the Americas (26%) while it remained similar to the previous week in the Western Pacific Region. A decrease in new weekly deaths was reported in the Eastern Mediterranean Region (11%), the European Region (10%) and in the South-East Asia Region (6%).
In this edition, we provide updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), and summarize their phenotypic characteristics based on available studies.

WHO Director General Speeches [selected]

WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches
Selected
13 January 2022 Speech
Director-General’s opening remarks at the 10th meeting of the IHR Emergency Committee on COVID-19 – 13 January 2022

13 January 2022 Speech
Director-General’s introductory remarks at Member State Information Session on COVID-19 – 13 January 2022

12 January 2022 Speech
WHO Director-General’s opening remarks at the media briefing on COVID-19 – 12 January 2022

COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements

COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

 

AstraZeneca
Press Releases
New Vaxzevria data further support its use as third dose booster
13 January 2022
::New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria
:: Additional analysis showed increased antibody response to Omicron after a third dose

Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
13 de Enero, 2022
Más del 82% de la población cubana completó su esquema de vacunación.
[More than 82% of the Cuban population completed their vaccination schedule.]

12 de Enero, 2022
Abdala muestra una seroconversión superior al 98% en población pediátrica.
[Abdala shows a seroconversion greater than 98% in the pediatric population.]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases – No new digest announcements identified

 

Novavax
Press Releases
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
Jan 12, 2022

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax’ COVID-19 Vaccine in South Africa
Jan 12, 2022

 

Pfizer
Recent Press Releases
01.12.2022
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released

01.10.2022
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
:: Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy
:: Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
11 January 2022 GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

 

Merck
News releases – No new digest announcements identified

 

Novartis
News
Media Release Jan 10, 2022
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

 

SK Biosciences
Press releases
SK bioscience Obtained Biologics License Application Approval of Novavax’ COVID-19 Vaccine in Korea
The first approval of a recombinant protein nanoparticle COVID-19 vaccine with proven efficacy and s…
2022. 01. 12

 

Valneva
Press Releases – No new digest announcements identified

COVID-19 Global Targets and Progress Tracker – IMF

COVID-19 Global Targets and Progress Tracker – IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

The Race for Global COVID-19 Vaccine Equity

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

 

Global Dashboard on COVID-19 Vaccine Equity

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 15 Jan 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

 

 

COVID-19 Data Explorer: Global Humanitarian Operations

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
15 Jan 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 318M total confirmed cases; 5.5M total confirmed deaths
Global vaccines administered: 9.57B
Number of Countries: 30
COVAX Allocations Round 4-9 (Number of Doses): 220M
COVAX Delivered (Number of Doses): 270M
Other Delivered (Number of Doses): 340M
Total Delivered (Number of Doses): 610M
Total Administered (Number of Doses): 460M

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]
https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.
The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.
Website accessed 15 Jan 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

 

HHS
HHS Secretary Becerra renews COVID-19 pandemic public health emergency declaration, marking two years of global pandemic response
Friday, January 14, 2022

 

 

FDA
Press Announcements
No new digest content identified.

 

 

Vaccines and Related Biological Products Advisory Committee– FDA
https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee
No meetings on calendar

 

 

::::::

 

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Fact Sheet: The Biden Administration to Begin Distributing At-Home, Rapid COVID-⁠19 Tests to Americans for Free
January 14, 2022 • Statements and Releases

Statement by President Joe Biden On the U.S. Supreme Court’s Decision on Vaccine Requirements
January 13, 2022 • Statements and Releases
…Today’s decision by the Supreme Court to uphold the requirement for health care workers will save lives:  the lives of patients who seek care in medical facilities, as well as the lives of doctors, nurses, and others who work there. It will cover 10.4 million health care workers at 76,000 medical facilities. We will enforce it.
At the same time, I am disappointed that the Supreme Court has chosen to block common-sense life-saving requirements for employees at large businesses that were grounded squarely in both science and the law. This emergency standard allowed employers to require vaccinations or to permit workers to refuse to be vaccinated, so long as they were tested once a week and wore a mask at work: a very modest burden.
As a result of the Court’s decision, it is now up to States and individual employers to determine whether to make their workplaces as safe as possible for employees, and whether their businesses will be safe for consumers during this pandemic by requiring employees to take the simple and effective step of getting vaccinated…

Press Briefing by White House COVID-⁠19 Response Team and Public Health Officials
January 12, 2022 • Press Briefings

FACT SHEET: Biden-⁠Harris Administration Increases COVID-⁠19 Testing in Schools to Keep Students Safe and Schools Open
January 12, 2022 • Statements and Releases

 

 

U.S. Department of State
https://www.state.gov/coronavirus/releases/
Media Notes
No new digest content identified.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

 

European Medicines Agency
News & Press Releases
News: Global regulators discuss path towards regulatory alignment on response to Omicron variant (new)
Last updated: 13/01/2022

 

 

News: Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant (new)
Last updated: 11/01/2022

 

 

News: EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-19 (new)
CHMP, PRAC, Last updated: 10/01/2022

 

 

::::::

 

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
News
Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 13 January 2022) EU/EEA
Epidemiological update – 14 Jan 2022
From 20 December 2021 to 2 January 2022, there were 21 EU/EEA countries with adequate sequencing volume that reported an estimated prevalence of Omicron VOC of 46%. COVID-19 case notification and hospital admission rates were high and increasing in most countries, while death and ICU admission rates remained stable. There is still limited evidence suggesting that the observed severity associated with Omicron VOC is lower than that associated with the Delta variant. Early studies suggest that current vaccines may be less effective against Omicron infection, although they still provide protection against hospitalisation and severe disease. Given the exponential growth advantage of Omicron VOC and the high numbers of cases, any potential benefits from a lower observed severity will be short-lived and outpaced by the sheer number of severe outcomes over time.

 

 

::::::

Accessed 15 Jan 2022
https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab

 

 

::::::

 

European Commission
https://ec.europa.eu/commission/presscorner/home/en
No new digest content identified.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

 

Government of India – Press Information Bureau
Latest Press Releases
COVID – 19 Vaccination Update – Day 365
:: India’s cumulative vaccination coverage achieves 156 crore landmark milestone
:: More than 57 lakh Vaccine doses administered today till 7 pm
Posted On: 15 JAN 2022 8:45PM by PIB Delhi

 

 

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

China is doubling down on its ‘zero-tolerance’ COVID policy ahead of the Olympics
National Public Radion [U.S.]
January 13, 2022 3:13 AM ET
TAIPEI, Taiwan — Just weeks before hosting the Beijing Winter Olympics, China is battling multiple coronavirus outbreaks in half a dozen cities, with the one closest to the capital driven by the highly transmissible omicron variant.
With the success of the Games and China’s national dignity at stake, Beijing is doubling down on its “zero-tolerance” COVID-19 policy.
Across China, more than 20 million people are in some form of lockdown, with many prevented from leaving their homes.
Tianjin, only about an hour from Beijing, is on high alert, although it has refrained from imposing a complete lockdown such as that in Xi’an, a city of 14 million.
Instead, it has sealed off several residential communities and universities, canceled almost all flights, suspended high speed train service and closed highways. People leaving the city are required to present negative COVID-19 tests and receive special permission.
The city conducted mass testing for a second time for its 14 million residents on Wednesday, and asked them to stay put in their homes until they receive a negative result…

POLIOPublic Health Emergency of International Concern (PHEIC)

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 12 January 2022
:: The WHO Executive Board is scheduled to take place on 24-29 January 2022.  The Secretariat has prepared two reports, which will inform Member State discussions, namely on polio eradication, and on polio transition planning and post-certification.
:: On polio eradication, the report provides an update on work towards Goals 1 and 2 of the Polio Eradication Strategy 2022–2026.  On transition and post-certification, the report provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018-2023) within the context of COVID-19.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
–  DR Congo:  two cVDPV2 cases
–  Yemen:  four cVDPV2 cases

 

::::::
::::::

Disease Outbreak News (DONs)

 

14 January 2022 | Influenza A (H5) – United Kingdom of Great Britain and Northern Ireland

::::::
::::::

 

WHO/OCHA Emergencies

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”
Afghanistan crisis [Last apparent update: 18 Oct 2021]

Crisis in Northern Ethiopia [Last apparent update: 1 June 2021]

Ebola outbreak, Democratic Republic of the Congo, 2021 [Last apparent update: 17 Aug 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 17 Aug 2021]

Coronavirus disease (COVID-19) pandemic [See COVID above]

 

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis [Last apparent update: 1 Oct 2021]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 17 Aug 2021]

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 17 Aug 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 13 September 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

 

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: ICCT Real-Time Response Overview Situation Report (11 January 2022)

 

Northern Ethiopia
Ethiopia – Northern Ethiopia Humanitarian Update Situation Report, 13 January 2022

 

::::::
::::::

WHO & Regional Offices [to 15 Jan 2022]

WHO & Regional Offices [to 15 Jan 2022]
https://www.who.int/
Selected News, Statements
14 January 2022
Statement
WHO recommends two new drugs to treat COVID-19

11 January 2022
Statement
Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)

::::::

 

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Omicron-fuelled COVID-19 surge in Africa plateaus 13 January 2022
After a six-week surge, Africa’s fourth pandemic wave driven primarily by the Omicron variant is flattening, marking the shortest-lived surge to date in the continent where cumulative cases have now exceeded 10 million…

WHO Region of the Americas PAHO
:: 13 Jan 2022 Study warns of high levels of depression and suicidal thoughts in Latin American health workers during pandemic
:: 12 Jan 2022 As COVID-19 cases nearly double in the Americas, health workers must be protected, PAHO says

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
Israel: Religious leaders bolster COVID-19 response with civil society and WHO/Europe support 14-01-2022
Healthy metaverse: how can we promote health online? 13-01-2022
Omicron wave threatening to overcome health workforce 11-01-2022
New data from Georgia, Kyrgyzstan, North Macedonia, Ukraine and Uzbekistan provides insights on health systems 10-01-2022

WHO Eastern Mediterranean Region EMRO
:: Independent evaluation of WHO’s Whole of Syria response, 2021 13 January 2022
:: WHO supports COVID-19 control measures in Islamic Republic of Iran with donation of new equipment 11 January 2022

WHO Western Pacific Region
No new digest content identified

 

::::::

WHO Events
https://www.who.int/news-room/events/2
[Selected]
150th session of the Executive Board
24 – 29 January 2022
Virtual event

19 January 2022
Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 19 January 2022

 

::::::

New WHO Publications
https://www.who.int/publications/i
Selected Titles
14 January 2022
Therapeutics and COVID-19: living guideline
Overview
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.
This eighth version of the WHO living guideline now contains 14 recommendations, including three new recommendations regarding Janus kinase (JAK) inhibitors and sotrovimab. No further updates to the previous existing recommendations were made in this latest version.

11 January 2022
SEA Region Measles and Rubella Quarterly update Jul -Sep 2021

10 January 2022
SEA Region Measles and Rubella Quarterly update Mar-Jun 2021

CDC/ACIP [U.S.] [to 15 Jan 2022]

CDC/ACIP [U.S.] [to 15 Jan 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements [Selected]
CDC updates consumer mask website to emphasize protection, fit, and comfort Friday, January 14, 2022
CDC has updated our consumer webpage describing the types of masks and respirators used to prevent the transmission of SARS-CoV-2. Masking is a critical public health tool to prevent the spread of COVID-19, and it is important to remember that any mask is better than no mask. To protect yourself and others from COVID-19, CDC continues to recommend that you wear the most protective mask you can that fits well and that you will wear consistently…

Readout of Dr. Walensky’s call with Disability Advocacy Groups and Allies Friday, January 14, 2022

CDC Study Shows Flu Vaccination Prevents Severe Flu Illness in U.S. Children Thursday, January 13, 2022

MMWR News Synopsis Friday, January 14, 2022

MMWR News Synopsis Friday, January 14, 2022
Selected Content
:: Supplement: Standards Required for the Development of CDC Evidence-Based Guidelines
:: Impact of the DREAMS Program on New HIV Diagnoses in Adolescent Girls and Young Women Attending Antenatal Care — Lesotho, 2015–2020
:: Previously Released: Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
:: Previously Released: Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years — United States, March 1, 2020–June 28, 2021

National Health Commission of the People’s Republic of China [to 15 Jan 2022]

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 15 Jan 2022]
http://en.nhc.gov.cn/
News
Nearly 2.92b COVID-19 vaccine doses administered on Chinese mainland
2022-01-14
Nearly 2.92 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Jan 13.

Nation plans to launch free HPV vaccinations
2022-01-14
China will gradually launch free human papillomavirus vaccinations nationwide to protect women and girls from cervical cancer, starting in pilot regions, the National Health Commission said.

National Medical Products Administration – PRC [to 15 Jan 2022]
http://english.nmpa.gov.cn/
News
Nearly 2.92b COVID-19 vaccine doses administered on Chinese mainland
2022-01-14
Nearly 2.92 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Jan 13.

CCDC Weekly Reports: Current Volume (4)
2022-01-14 / No. 2
View  PDF of this issue
:: Perspectives: Public Health Control Measures for the Co-circulation of Influenza and SARS-CoV-2 During Influenza Seasons
:: Notes from the Field: Cholera Caused by a New Clone of Serogroup O1 Vibrio cholerae — Beijing Municipality, China, June 2021
:: Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, November, 2021

Organization Announcements

::::::

 

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

 

Airfinity
https://www.airfinity.com/insights
INSIGHTS & COMPANY NEWS
240 million COVID-19 vaccines set to expire by March, according to analysis by Airfinity
Jan 12, 2022
Airfinity estimates 241 million COVID-19 vaccine doses purchased by the G7 and EU will go unused and expire by March this year.
In September 2021, Airfinity forecast 100 million vaccines would expire by the end of 2021. Today UNICEF said poorer nations rejected more than 100 million doses in December alone due to a short shelf life. 
Airfinity’s forecast is based on analysis of G7 and EU vaccine supply while accounting for doses administered, boosters for everyone over 12 years-old, vaccine hesitancy and donations.
Co-founder and CEO of Airfinity, Rasmus Bech Hansen says, “These numbers show that vaccinating the world is now largely a distribution problem and no longer a supply issue. Even after successful booster rollouts, there are surplus doses available that risk going to waste if not shared very soon. The emergence of Omicron and the likelihood of future variants shows there is no time to waste.”
Dr Matt Linley, Lead Analyst at Airfinity, says, “Countries need these vaccines to have a minimum shelf life of two months, otherwise there isn’t enough time to get them to the people who need them. Once this two month requirement is factored into our analysis the number of potentially wasted doses could rise to 500 million by March.”

Paul G. Allen Frontiers Group [to 15 Jan 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BARDA – U.S. Department of HHS [to 15 Jan 2022]
https://www.phe.gov/about/barda/Pages/default.aspx
News
HHS Secretary Becerra renews COVID-19 pandemic public health emergency declaration, marking two years of global pandemic response
Friday, January 14, 2022

DOD, HHS Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS’ 500 Million Free At-Home COVID-19 Tests
Thursday, January 13, 2022

BMGF – Gates Foundation [to 15 Jan 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 15 Jan 2022]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 15 Jan 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 15 Jan 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – January 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations [to 15 Jan 2022]
http://cepi.net/
Latest News
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 15 Jan 2022
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 15 Jan 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 15 Jan 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [to 15 Jan 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 15 Jan 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Fondation Merieux [to 15 Jan 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 15 Jan 2022]
https://www.gavi.org/
News Releases
No new digest content identified.

GHIT Fund [to 15 Jan 2022]
https://www.ghitfund.org/newsroom/press
January 11, 2022
GHIT Fund Announces Appointment of Dr. Osamu Kunii as New CEO
The Global Health Innovative Technology Fund (GHIT) today announced the appointment of Dr. Osamu Kunii as the organization’s new CEO, effective March 1st, 2022. Dr. Osamu Kunii is currently serving as a Management Executive Committee member of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as Head of the Strategy, Investment and Impact Division…

Global Fund [to 15 Jan 2022]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 15 Jan 2022]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 15 Jan 2022]
http://www.hillemanlabs.org/
News & Insights
No new digest content identified.

HHMI – Howard Hughes Medical Institute [to 15 Jan 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 15 Jan 2022]
http://www.humanvaccinesproject.org/
News
HVP COVID Report
Jan 13, 2022
Eric Topol: “We got Lucky with Omicron”

IAVI [to 15 Jan 2022]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

ICRC [to 15 Jan 2022]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
Ukraine: Ongoing, active conflict a cause of a heavy humanitarian toll
A statement from Dominik Stillhart, the director of operations for the ICRC
12-01-2022 | Statement

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 15 Jan 2022]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
South Asia: Omicron threatens to overwhelm health systems
12/01/2022 | Press release
Kuala Lumpur/Delhi, 12 January 2022: The Omicron variant is fuelling a rapid surge of COVID-19 across South Asia that threatens to overwhelm health systems still reeling from a deadly wave of the Delta variant last year.
Countries across South Asia from India to Nepal and Bangladesh are reporting alarming increases in COVID-19 infections, with India alone reporting a 2,013 per cent increase in COVID-19 infections in the past month, with cases now topping 179,000 in a day.
The new wave is causing further misery for hundreds of millions of people across South Asia, already living in extreme poverty, exacerbated by COVID-19 over the past two years.
Udaya Regmi, International Federation of Red Cross and Red Crescent Societies (IFRC) Head of Delegation, South Asia, said: “This latest surge of COVID-19 spells immense danger for millions of people and health systems across South Asia. Omicron is spreading fast and while vaccination rates have been soaring, after such tragic loss of life last year, fear is mounting of record infection rates.
“People everywhere want this pandemic to end but we must boost efforts to keep people safe with the basics, by wearing masks, avoiding crowds, and getting fully vaccinated where possible.”…

Institut Pasteur [to 15 Jan 2022]
https://www.pasteur.fr/en/press-area
Press Documents
Press release 11.01.2022
Identification of a novel therapeutic target in Multiple Myeloma
Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome…

IOM / International Organization for Migration [to 15 Jan 2022]
http://www.iom.int/press-room/press-releases
News – Selected
No new digest content identified.

ISC / International Science Council [to 15 Jan 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News
No new digest content identified.

IVAC [to 15 Jan 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [to 15 Jan 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 15 Jan 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
Experts Encourage School Administrators to Reduce COVID-19 Transmission by Improving Indoor Air in Schools
January 11, 2022

MSF/Médecins Sans Frontières [to 15 Jan 2022]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine – USA [to 15 Jan 2022]
https://nam.edu/programs/
Selected News/Programs/Events
No new digest content identified.

National Academy of Sciences – USA [to 15 Jan 2022]
http://www.nasonline.org/news-and-multimedia/
News
No new digest content identified.

National Vaccine Program Office – U.S. HHS [to 15 Jan 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee [NVAC] 2022 Meetings
February 10-11, 2022

NIH [to 15 Jan 2022]
http://www.nih.gov/news-events/news-releases
News Releases
No new digest content identified.

OECD [to 15 Jan 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
Newsroom
No new digest content identified.

PATH [to 15 Jan 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Sabin Vaccine Institute [to 15 Jan 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 15 Jan 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 15 Jan 2022]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
No new digest content identified.

UNICEF [to 15 Jan 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
No new digest content identified.

Unitaid [to 15 Jan 2022]
https://unitaid.org/
Featured News
2 January 2022
FIND and Unitaid, through the ACT-Accelerator, seek organizations to advocate and raise awareness on COVID-19 testing and treatment solutions
FIND and Unitaid today launched a request for proposals (RFP) to select services of organizations, with a proven record of advocacy and awareness-raising in healthcare in low- and middle-income countries, to implement projects to achieve the below specific objectives:
Increase access and uptake to COVID-19 testing and therapeutics, as they get recommended, through development and implementation of robust and evidence-based advocacy strategies supported by advocacy, literacy and communication materials and initiatives adapted to specific population groups, regional and country contexts
Disseminate and amplify these materials and initiatives through appropriate communication channels to increase prioritization of COVID-19 testing and linkage to treatment in the national pandemic response as well as generate demand for testing and therapeutics within relevant target groups
…The total budget envelope for this RFP is anticipated to be US$ ~2 million. This amount will be distributed among selected partners with an average award of no less than US$50,000 to a maximum of US$100,000. Proposals along with appendices/supporting documents must be received by FIND at [advocacy_RFP@finddx.org] no later than 2 February 2022 at 17h00 CET. Two applicant webinars are being organized to provide an overview of the RFP and answer queries. These webinars will take place on 19 January and 20 January.

USAID [to 15 Jan 2022]
https://www.usaid.gov/news-information/press-releases/2021
Selected Press Releases, Statements, Announcements
No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 15 Jan 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin) [to 15 Jan 2022]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

Vaccine Confidence Project [to 15 Jan 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 15 Jan 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 15 Jan 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
News
Wellcome’s new strategy gets extra boost, as organisation makes strongest returns in over two decades
10 January 2022
Wellcome is making its biggest funding commitment to science and health in our 85-year history, thanks to our strongest investment returns in 25 years.
[See Perspective above for detail]

The Wistar Institute [to 15 Jan 2022]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 15 Jan 2022]
https://www.wfpha.org/
Latest News – Blog
No new digest content identified.

World Bank [to 15 Jan 2022]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Global Growth to Slow through 2023, Adding to Risk of ‘Hard Landing’ in Developing Economies
Spread of COVID-19 Variants Alongside Inflation, Debt, and Inequality Intensifies Uncertainty WASHINGTON, Jan. 11, 2022—Following a strong rebound in 2021, the global economy is entering a pronounced slowdown…
Date: January 11, 2022 Type: Press Release
[See Perspectives above for detail]

World Bank Statement at the 8th Facilitation Council Meeting of the Access to COVID-19 Tolls Accelerator (ACT-A)
Let me reiterate the World Bank Group’s support for ACT-A’s objectives. We continue to be an engaged partner of ACT-A and we support its shared objective of expanding equitable and affordable access to…
Date: January 10, 2022 Type: Speeches and Transcripts
[See Perspectives above for detail]

World Organisation for Animal Health (OIE) [to 15 Jan 2022]
https://www.oie.int/en/media/news/
Press Releases, Statements
No new digest content identified.

WTO – World Trade Organisation [to 15 Jan 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
General Council discusses India’s call for virtual ministerial meeting on pandemic response
10 January 2022
[See Perspective above for detail]

 

::::::

ARM [Alliance for Regenerative Medicine] [to 15 Jan 2022]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest content identified.

BIO [to 15 Jan 2022]
https://www.bio.org/press-releases
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 15 Jan 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 15 Jan 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 15 Jan 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
Vivian Frittelli takes over the position of IGBA Chair
Geneva, 12 January 2022
IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global
manufacturers of generic and biosimilar medicines, announced today that Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM), is taking over the position of IGBA Chair for 2022 from Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA)…

International Alliance of Patients’ Organizations – IAPO [to 15 Jan 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA [to 15 Jan 2022]
http://www.phrma.org/
Latest News [Selected]
No new digest content identified.

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Inequity Along the Medical/Dental Divide

AMA Journal of Ethics
Volume 24, Number 1: E1-105 Jan 2022
https://journalofethics.ama-assn.org/issue/inequity-along-medicaldental-divide

 

Inequity Along the Medical/Dental Divide
Dental and medical health systems in the United States have evolved as fully separate entities. This division exacerbates health inequity, since patients’ poor oral health affects their general health. The professionally entrenched view that what’s in patients’ mouths is somehow isolated from what’s going on in the rest of their bodies is one all clinicians need to resist, since this view can be a source of harm, particularly among vulnerable patients and communities. Practical and ethical strategies for better aligning medical and dental goals of care are considered in this issue.

Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis

Artificial Intelligence – An International Journal
Volume 302 January 2022
https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C

 


BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 15 Jan 2022)
Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis
Authors: Sigal Maya, Guntas Padda, Victoria Close, Trevor Wilson, Fareeda Ahmed, Elliot Marseille and James G. Kahn
Content type: Research
15 January 2022

Women’s views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: a multi-methods study in the UK

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 15 Jan 2022)

 

Women’s views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: a multi-methods study in the UK
COVID-19 vaccines are advised for pregnant women in the United Kingdom (UK) however COVID-19 vaccine uptake among pregnant women is inadequate.
Authors: Helen Skirrow, Sara Barnett, Sadie Bell, Lucia Riaposova, Sandra Mounier-Jack, Beate Kampmann and Beth Holder
Citation: BMC Pregnancy and Childbirth 2022 22:33
Content type: Research
Published on: 14 January 2022

Vaccination against tuberculosis, polio and hepatitis B at birth in Podor health district, Northern Senegal: cross-sectional study of vaccination coverage and its associated factors

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Jan 2022)

 

Vaccination against tuberculosis, polio and hepatitis B at birth in Podor health district, Northern Senegal: cross-sectional study of vaccination coverage and its associated factors
In Senegal, studies focusing specifically on vaccination coverage with the Bacille de Calmette et Guérin (BCG) vaccine, the birth dose of oral polio vaccine (OPV zero dose) and the birth dose of hepatitis B (H…
Authors: Oumar Bassoum, Ndeye Mareme Sougou, Mouhamadou Faly Ba, Malick Anne, Mamoudou Bocoum, Alioune Dieye, Cheikh Sokhna and Anta Tal-Dia
Citation: BMC Public Health 2022 22:110
Content type: Research
Published on: 15 January 2022

COVID-19 vaccine hesitancy in the UK: a longitudinal household cross-sectional study

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Jan 2022)

 

COVID-19 vaccine hesitancy in the UK: a longitudinal household cross-sectional study
The approved COVID-19 vaccines have shown great promise in reducing disease transmission and severity of outcomes. However, the success of the COVID-19 vaccine rollout is dependent on public acceptance and wil…
Authors: Kausik Chaudhuri, Anindita Chakrabarti, Joht Singh Chandan and Siddhartha Bandyopadhyay
Citation: BMC Public Health 2022 22:104
Content type: Research article
Published on: 15 January 2022

Vaccination, politics and COVID-19 impacts

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Jan 2022)

 

Vaccination, politics and COVID-19 impacts
The development of safe and effective COVID-19 vaccines provides a clear path to bring the pandemic to an end. Vaccination rates, however, have been insufficient to prevent disease spread. A critical factor in…
Authors: Don Albrecht
Citation: BMC Public Health 2022 22:96
Content type: Research
Published on: 14 January 2022

Original research: Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis—implications for public health communications in Australia

BMJ Open
January 2022 – Volume 12 – 1
https://bmjopen.bmj.com/content/12/1

 

Original research: Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis—implications for public health communications in Australia (3 January, 2022)
Joanne Enticott, Jaskirath Singh Gill, Simon L. Bacon, Kim L. Lavoie, Daniel S. Epstein, Shrinkhala Dawadi, Helena J Teede, Jacqueline Boyle

Original research: Factors associated with COVID-19 vaccine receipt at two integrated healthcare systems in New York City: a cross-sectional study of healthcare workers (6 January, 2022)

BMJ Open
January 2022 – Volume 12 – 1
https://bmjopen.bmj.com/content/12/1

 

Original research: Factors associated with COVID-19 vaccine receipt at two integrated healthcare systems in New York City: a cross-sectional study of healthcare workers (6 January, 2022)
Kristin Oliver, Anant Raut, Stanley Pierre, Leopolda Silvera, Alexander Boulos, Alyssa Gale, Aaron Baum, Ashley Chory, Nichola J Davis, David D’Souza, Amy Freeman, Crispin Goytia, Andrea Hamilton, Carol Horowitz, Nadia Islam, Jessica Jeavons, Janine Knudsen, Sheng Li, Jenna Lupi, Roxanne Martin, Sheela Maru, Ismail Nabeel, Dina Pimenova, Anya Romanoff, Sonya Rusanov, Nina R Schwalbe, Nita Vangeepuram, Rachel Vreeman, Joseph Masci, Duncan Maru

Data gaps towards health development goals, 47 low- and middle-income countries

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

 

Research
Data gaps towards health development goals, 47 low- and middle-income countries
Luhua Zhao, Bochen Cao, Elaine Borghi, Somnath Chatterji, Sebastian Garcia-Saiso, Arash Rashidian, Henry Victor Doctor, Marcelo D’Agostino, Humphrey C Karamagi, David Novillo-Ortiz, Mark Landry, Ahmad Reza Hosseinpoor, Abdisalan Noor, Leanne Riley, Adrienne Cox, Jun Gao, Steve Litavecz, Samira Asma
Bull World Health Organ. 2022 Jan 1; 100(1): 40–49. Published online 2021 Nov 4. doi: 10.2471/BLT.21.286254
PMCID: PMC8722627

Comparison of national antimicrobial treatment guidelines, African Union

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

 

Comparison of national antimicrobial treatment guidelines, African Union
Jessica Craig, Kayli Hiban, Isabel Frost, Geetanjali Kapoor, Yewande Alimi, Jay K Varma
Bull World Health Organ. 2022 Jan 1; 100(1): 50–59. Published online 2021 Nov 26. doi: 10.2471/BLT.21.286689
PMCID: PMC8722630

Achieving sustainable health equity

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

 

Perspectives
Achieving sustainable health equity
Arachu Castro, Michael Marmot, Juan Garay, Armando de Negri, Paulo Buss, on behalf of the Sustainable Health Equity Movement
Bull World Health Organ. 2022 Jan 1; 100(1): 81–83. Published online 2021 Nov 25. doi: 10.2471/BLT.21.286523
PMCID: PMC8722628

Interdisciplinary Information for Infectious Disease Response: Exercising for Improved Medical/Public Health Communication and Collaboration

Disaster Medicine and Public Health Preparedness
Volume 15 – Issue 5 – October 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

 

Policy Analysis
Interdisciplinary Information for Infectious Disease Response: Exercising for Improved Medical/Public Health Communication and Collaboration
Saskia Popescu, Nathan Myers
Published online by Cambridge University Press: 08 September 2020, pp. 546-550

Understanding the Predictors that Contribute to Liberian Health Care Workers Feeling Protected From Ebola While at Work

Disaster Medicine and Public Health Preparedness
Volume 15 – Issue 5 – October 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

 

Original Research
Understanding the Predictors that Contribute to Liberian Health Care Workers Feeling Protected From Ebola While at Work
Kayla Enriquez, Kanagasabai Udhayashankar, Michelle Niescierenko
Published online by Cambridge University Press: 29 May 2020, pp. 589-594